Research on global patent technology profile of dolutegravir: an anti-AIDS drug
ZHAO Chang-kuo
WANG Xian-heng
CAO Ying
XU Lang
YUAN Zhi
Abstract：Dolutegravir is currently the most popular anti-AIDS drug as an integrase inhibitor,which has been approved by US FDA in August,2013,while still not enter Chinese market.Dolutegravir can significantly improve the patient's condition.A detailed understanding of the drug patent declaration trends,and in-depth analysis of the overall layout of the patent and technical context,can provide relevant information and references for our generic and innovative drug companies,on the development of generic drug of dolutegravir and "me-too" and "me-better" innovative drugs.
Keywords：dolutegraviranti-AIDSpatent layoutgeneric druginnovative drug
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2003-2007 )